Odyssey Health, Inc. Extends Maturity Dates on Promissory Notes

Odyssey Health, Inc. (OTC:ODYY), a Nevada-based medical device company, has announced the extension of maturity dates on two of its financial agreements as disclosed in a recent 8-K filing with the SEC.

The company entered into an agreement on Sunday, February 13, 2025, with Jon Lutz, an accredited investor, to extend the maturity date of a promissory note originally dated February 13, 2024. The amendment, known as Amendment No. 3, pushes the due date to July 31, 2025, while maintaining the original terms and conditions of the note.

Additionally, on Wednesday, February 19, 2025, with an effective date of December 31, 2024, Odyssey Health amended a convertible promissory note under the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC. This amendment, referred to as Amendment No. 9, also extends the maturity date to July 31, 2025, without altering other terms and conditions.

The extensions provide Odyssey Health with more time to fulfill its financial obligations under these agreements. The details of the amendments were attached as exhibits to the 8-K filing, which serves as the source of this information.

The company, known for its work in the surgical and medical instruments sector, did not disclose the specific financial implications of these extensions. However, such amendments are typically negotiated to give companies more flexibility in managing their capital structure and liquidity.

Odyssey Health’s business address is at 2300 West Sahara Avenue, Suite 800-#4012, Las Vegas, NV 89102, and can be contacted via phone at 702-780-6559. The company’s CEO, Joseph Michael Redmond, signed off on the SEC filing, ensuring compliance with regulatory requirements.

Investors and interested parties can refer to the SEC filing for a more detailed account of the amendments and their terms. The adjustments to the maturity dates reflect Odyssey Health’s ongoing financial management strategies as it continues its operations within the medical device industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.